Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US9682041B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | May 2, 2014 |
| Grant date | Jun 20, 2017 |
| Priority date | — |
| Expiry date | May 24, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/907
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.